- Clinical presentation and initial assessment
- Imaging modalities for mild traumatic brain injury
- Indications for neuroimaging
- Findings and prognostic significance
- Limitations and future directions
Mild traumatic brain injury (mTBI) typically presents with a range of subtle and often transient neurological and cognitive symptoms following an external force to the head. Common clinical features include brief loss of consciousness, confusion, headache, dizziness, nausea, blurred vision, and difficulty with memory or concentration. In some cases, patients may not initially seek medical attention as symptoms are perceived to be minor or may develop hours after the injury.
Healthcare professionals rely on a thorough clinical assessment to determine the severity and nature of the injury. This includes taking a detailed history of the injury event, evaluating symptoms, and performing a neurological examination. The Glasgow Coma Scale (GCS) is frequently used to assess the level of consciousness, with scores ranging from 13 to 15 generally indicative of mTBI. Other elements such as amnesia, post-traumatic confusion, and balance disturbances also play a role in suspecting mTBI.
Early identification of high-risk features is crucial for appropriate triage and the need for neuroimaging. For instance, signs such as repeated vomiting, seizures, focal neurological deficits, or a worsening mental status may indicate more severe intracranial pathology despite an initial mTBI diagnosis. In emergency settings, clinical decision rules—such as the Canadian CT Head Rule and the New Orleans Criteria—assist clinicians in determining whether a CT scan is necessary based on the clinical presentation.
In cases where CT findings are normal but symptoms persist or worsen, further evaluation with MRI may be warranted. MRI is more sensitive than CT in detecting subtle intracranial abnormalities such as microbleeds or diffuse axonal injury, which are often associated with more complex presentations of mTBI. Thus, while initial clinical assessment remains the cornerstone of diagnosis, it is often complemented by neuroimaging to ensure accurate evaluation and appropriate management.
Imaging modalities for mild traumatic brain injury
Multiple imaging modalities are available for the assessment of mTBI, each with distinct advantages and limitations depending on the clinical context. Computed tomography (CT) remains the first-line neuroimaging tool in acute settings due to its wide availability, rapid acquisition time, and high sensitivity for detecting acute haemorrhage, skull fractures, and other structural abnormalities. It is particularly valuable in identifying clinically significant intracranial pathology that may necessitate urgent intervention.
Despite its utility in acute injury evaluation, CT has limited sensitivity in detecting microscopic injuries frequently present in mTBI, such as diffuse axonal injury (DAI) or small contusions. For this reason, magnetic resonance imaging (MRI) is often employed when symptoms persist beyond the acute phase or when CT is inconclusive. MRI offers superior soft tissue contrast and is more capable of identifying subtle injuries such as microhaemorrhages, white matter changes, and signs of neuroinflammation, which may not be apparent on CT scans. Sequences such as susceptibility-weighted imaging (SWI) and diffusion tensor imaging (DTI) can provide additional insight into axonal integrity and vascular injury, enhancing the diagnostic yield in complex cases.
Advanced MRI techniques are increasingly used in research and clinical settings to assess structural and functional changes resulting from mTBI. Functional MRI (fMRI), proton magnetic resonance spectroscopy (MRS), and arterial spin labelling (ASL) allow for the evaluation of neuronal activity, metabolic changes, and cerebral perfusion, respectively. While these modalities hold potential for improving mTBI diagnosis and monitoring recovery trajectories, their routine use in clinical practice is currently limited due to variability in interpretation, cost, and technological requirements.
Other imaging techniques such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET) have also been explored in the context of mTBI, particularly for identifying alterations in cerebral blood flow and metabolism. However, these tools are largely restricted to research environments and are not commonly used in standard clinical pathways for mTBI evaluation.
Ultimately, the choice of imaging modality is guided by factors such as the timing of the injury, the patient’s clinical presentation, and the availability of imaging resources. While CT remains essential for initial triage and exclusion of significant acute abnormalities, MRI provides a more comprehensive evaluation of the subtle brain changes often responsible for persistent post-concussive symptoms. Integration of neuroimaging data with clinical findings is essential for an accurate and nuanced diagnosis of mTBI.
Indications for neuroimaging
The decision to perform neuroimaging in patients with mild traumatic brain injury is influenced by a careful evaluation of clinical risk factors, symptom severity, and the likelihood of uncovering clinically significant findings. Given that most cases of mTBI result in no visible abnormalities on standard imaging, neuroimaging is not universally indicated and should be reserved for situations where it could impact clinical management or identify complications requiring intervention.
Clinical decision rules, such as the Canadian CT Head Rule and the New Orleans Criteria, are widely used to identify patients at higher risk of intracranial injuries who warrant neuroimaging. These rules incorporate factors such as loss of consciousness, amnesia, vomiting, age, signs of skull fracture, and neurological deficits. For example, a patient over the age of 65 who presents with a history of a fall and brief loss of consciousness may meet criteria for immediate CT scanning, even if their Glasgow Coma Scale score is 15. Similarly, anticoagulated patients are often imaged more readily due to an elevated risk of intracranial bleeding, even in the absence of overt neurological symptoms.
Urgent CT scanning is generally indicated in cases where there is evidence of deteriorating neurological status, focal deficits, suspected skull fracture, or high-energy mechanism of injury. In paediatric populations, the use of guidelines such as the PECARN rule helps limit unnecessary exposure to ionising radiation while still identifying those most likely to benefit from CT imaging. For adults, clinicians must balance the relatively low yield of CT in uncomplicated mTBI against the potential severity of missed diagnoses, such as subdural or epidural haematomas.
When initial CT imaging is negative yet symptoms persist beyond the expected recovery window—typically two weeks—or when cognitive deficits interfere with the individual’s daily functioning, further evaluation with MRI may be indicated. MRI is particularly valuable for detecting non-haemorrhagic lesions, white matter abnormalities, and signs of diffuse axonal injury that are not visible on CT. For certain high-risk groups, such as athletes with repetitive head trauma, military personnel, or individuals involved in motor vehicle collisions, the threshold for considering MRI may be lower due to higher suspicion of underlying structural changes.
Neuroimaging is also considered in medico-legal contexts or when establishing a baseline for future symptom monitoring is deemed necessary. In such settings, MRI findings may support a diagnosis of mTBI when clinical symptoms are vague or overlap with psychiatric conditions like depression or anxiety. Although imaging is not the primary diagnostic tool for mTBI, it provides valuable anatomical and functional insights, especially when used selectively in accordance with clinical criteria and evidence-based guidelines.
Findings and prognostic significance
Neuroimaging findings in patients with mild traumatic brain injury (mTBI) are often subtle or even absent on conventional imaging, which can complicate both diagnosis and prognostication. However, when abnormalities are detected, they may hold significant implications regarding the severity of injury and expected recovery trajectory. On CT, findings that may be present in mTBI include small subdural or epidural haematomas, cerebral contusions, and skull fractures. Although such findings are uncommon in the majority of mTBI cases, their presence typically indicates a more severe injury phenotype and may necessitate closer observation or neurosurgical intervention.
MRI offers a more sensitive method of detection for mTBI-related abnormalities, particularly in cases where CT scans are normal but symptoms are persistent or unexplained. MRI can reveal diffuse axonal injury, microhaemorrhages, and white matter changes, often using susceptibility-weighted imaging (SWI) or diffusion tensor imaging (DTI). These findings are associated with disrupted neuronal integrity and can correlate with neurocognitive impairment, including issues with memory, attention, and executive function. DTI metrics, such as reduced fractional anisotropy, are considered indicative of compromised white matter tracts and may serve as biomarkers for injury severity.
From a prognostic standpoint, MRI abnormalities may provide insight into which patients are at risk of prolonged symptoms or post-concussion syndrome (PCS). For example, individuals with diffuse axonal injuries or multiple microbleeds on initial imaging studies are more likely to experience extended recovery periods and functional difficulties. These imaging findings have been associated with delayed return to work, decreased quality of life, and heightened vulnerability to subsequent head injuries. Therefore, imaging not only assists in confirming an mTBI diagnosis but also contributes to establishing realistic expectations for recovery.
In contrast, the absence of visible abnormalities on neuroimaging does not necessarily rule out clinically significant dysfunction following mTBI. Many patients report ongoing symptoms in the absence of correlating structural changes, highlighting the limitations of current imaging technologies in capturing the full spectrum of brain injury. In such cases, functional imaging techniques—including functional MRI (fMRI) or magnetic resonance spectroscopy (MRS)—may reveal alterations in cerebral activation or metabolism, suggesting more diffuse or biochemical injury components not seen on standard structural scans. While these methods are promising, they are still largely confined to research settings and are not yet incorporated widely into routine clinical practice.
Imaging findings may also guide therapeutic decisions and inform return-to-play or return-to-work protocols, particularly in high-risk groups such as athletes and military personnel. Imaging that shows persistent abnormalities can lead to more conservative management strategies, whereas normal findings, in conjunction with clinical improvement, may support earlier reintegration. As part of a comprehensive assessment strategy, neuroimaging plays a critical role not only in the diagnosis of mTBI but in predicting outcomes and individualising patient care plans.
Limitations and future directions
Despite the progress in neuroimaging techniques for evaluating mild traumatic brain injury (mTBI), several limitations persist that can hinder both diagnosis and management. One of the primary challenges is the relatively low sensitivity of standard imaging modalities, particularly CT, in detecting subtle brain injuries characteristic of mTBI. While CT remains the first-line modality for acute assessment due to its ability to rule out life-threatening lesions such as haemorrhage or skull fracture, it often fails to reveal microstructural damage, such as diffuse axonal injury or minor contusions, which are common in mTBI but not visible on conventional scans.
MRI, although more sensitive than CT, is not without its drawbacks. Access to MRI can be limited by availability, cost, and patient contraindications, such as implanted medical devices or claustrophobia. Furthermore, even advanced MRI techniques, including diffusion tensor imaging and susceptibility-weighted imaging, may yield findings that are difficult to interpret consistently across institutions. The lack of standardised imaging protocols and consensus on what constitutes clinically significant abnormalities in mTBI further complicates the utility of MRI in everyday clinical practice.
Another significant limitation is the uncertain relationship between imaging findings and clinical symptoms. Many patients with mTBI demonstrate ongoing cognitive, emotional, or vestibular symptoms despite normal findings on MRI or CT. Conversely, some individuals may exhibit detectable abnormalities on imaging without corresponding symptoms, presenting a challenge in linking imaging results to functional outcomes. This disconnect underscores the complexity of mTBI pathology and the need for more integrative diagnostic approaches that combine neuroimaging with comprehensive clinical, cognitive, and functional assessments.
In the context of prognostication, while some imaging abnormalities such as microhaemorrhages or white matter disruptions have been associated with poorer outcomes, they are neither sufficiently sensitive nor specific to serve as standalone predictors. The variability in imaging findings and their clinical significance points to a need for larger, longitudinal studies that can better define the prognostic value of neuroimaging in mTBI. Without robust predictive markers, tailoring treatment plans and providing accurate recovery timelines remains speculative in many cases.
Future directions in the field aim to address these challenges through several avenues. One major area of development is the refinement of advanced imaging techniques to detect subtle brain injuries with greater accuracy and reproducibility. Functional imaging modalities, such as functional MRI and positron emission tomography, hold promise in exploring alterations in brain networks and metabolic function, providing a more comprehensive picture of injury beyond structural damage. However, these technologies require standardisation, validation, and integration into clinical workflows before they can impact routine diagnosis meaningfully.
Additionally, there is growing interest in the use of artificial intelligence and machine learning algorithms to enhance the interpretation of neuroimaging data. These tools can potentially identify complex patterns that may not be evident through conventional analysis, improving diagnostic precision and aiding in the stratification of patients based on predicted outcomes. Efforts are also underway to develop imaging biomarkers that can better correlate with symptom severity, recovery trajectories, and susceptibility to long-term complications.
Among paediatric populations and vulnerable groups such as the elderly or individuals with prior TBIs, research is focusing on defining age-specific imaging criteria and thresholds for diagnosis. Given that neurodevelopmental and degenerative changes can mimic or mask mTBI-related findings on imaging, tailoring diagnostic approaches to these cohorts will be vital for accurate and ethical clinical care.
Ultimately, the goal is to move towards a more personalised model of care where neuroimaging, alongside clinical data, informs not only the diagnosis of mTBI but also guides rehabilitation strategies and supports informed decision-making about return to life activities. Continued investment in research, standardisation of imaging protocols, and cross-disciplinary collaboration will be essential to overcoming current limitations and advancing the role of imaging in the management of mTBI.
